The abstract is read at the publisher; the summary is JClub's.
A CD7-engaging AAV.APR31 variant with an APR motif at residues 455–457 enables robust in vivo engineering of primary human T and NK cells at nearly 100–1,000-fold lower doses than AAV6.
- Why it matters: AAV6’s limited tropism restricts efficient genome engineering in human T cells, limiting translational potential compared with more effective but less flexible delivery approaches.
- What they did: The team directed evolution of the AAV6 capsid in primary human T cells, then used CRISPR screening and structural analysis to link enhanced entry to CD7 alongside AAVR.
- The result: AAV.APR31 supported transient transgene delivery, site-specific knock-in, and transposon integration, producing CAR-T cells functionally equivalent to lentiviral products and enabling potent tumor control in hematologic and solid tumor mouse models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.